Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

B

Beth Israel Deaconess Medical Center

Other

0

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

0

Indications↗

Distinct diseases across all programs

42

Clinical Trials↗

All sponsored trials (all statuses)

Activity

Recent Activity

Last 14 days

An Open-label Proof of Concept Study Regarding the Efficacy and Safety of Dupilumab in the Treatment of Keloids

Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy

Active, not recruiting

Building Respiratory Support in East Africa Through High Flow Versus Standard Flow Oxygen Evaluation

Earlier

Sep 5, 2026TrialEffect of a Brief Daily Digital Meditation on Well-Being in US Young Adults (BEGIN II)

Aug 29, 2026TrialEvaluating the Efficacy and Safety of Saline Irrigation as an Add-On Therapy for Retained Pleural Infections (LYTICS +)

Aug 29, 2026TrialInter-lobar Fissure Completion as a Salvage Treatment in Patients With Failed Bronchoscopic Lung Volume Reduction

Aug 29, 2026TrialGastrointestinal Dopamine Decarboxylase and Levodopa Pharmacokinetics

Aug 28, 2026TrialImplementation of Low-Cost Single-Use Flexible Bronchoscopes for Routine Interventional Pulmonary Procedures: A Feasibility Study

3 more events

Aug 28, 2026TrialA Pilot Assessment of the Safety and Efficacy of Pleural Irrigation for Retained Pleural Infection Using a Novel Irrigation Device

Aug 27, 2026TrialTargeting Allopregnanolone to Probe Behavioral and Neurobiological Mechanisms That Underlie Depression in Women Across the Menopause Transition

Aug 27, 2026TrialVentilation-Perfusion Matching and PEEP Titration in Patients Undergoing Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation (VA ECMO)

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)